TF and cancer: The anti-TF-IgM serum level was significantly lower in cancer patients than in blood donors (P = 0.0024) and the benign diseases group (P = 0.0004) and for the combined group of controls (P = 0.0001), with no relation to the stage of cancer (Figure 1(b)).